Article

James C. Capretta, MA, Discusses How to Deliver Better Value to Patients

James C. Capretta, MA, answers what process can be put in place for continual improvement in the productivity and quality of patient care.

James C. Capretta, MA, Fellow, Ethics and Public Policy Center (EPPC), states that a market driven by consumers with government oversight would drive higher quality and lower costs over time.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
Interview with Miriam Freimer, MD, The Ohio State University Wexner Medical Center
Merrill H. Stewart, MD
Dr Carrie Kitko
Jeffrey Fitzgerald, JD
Dr Carrie Kitko
Related Content
Graphic of a person cutting a health care price tag in half | Image credit: retrostar - stock.adobe.com
July 11th 2025

The Future of Drug Pricing: Most Favored Nation, PBMs, and Patient Access

Laura Joszt, MA
During the Reshaping Rx: Navigating 2025 Drug Pricing Policies webinar, panelists discussed the Most Favored Nation executive order, bills aimed at pharmacy benefit managers (PBMs), and other drug pricing policies.
Managed Care Cast
July 8th 2025

Managed Care Cast News Roundup: July 8, 2025

Giuliana Grossi
Medical societies challenge HHS Secretary Robert F. Kennedy Jr's COVID-19 vaccine rollbacks, and more news updates from the week.
Medicaid | Image credit: Andrii - stock.adobe.com
July 10th 2025

Experts Highlight Consequences of Medicaid Rollbacks Due to Budget Bill

Julia Bonavitacola
A webinar held by KFF on July 9 emphasized the immediate effects of the new budget bill, highlighting the impacts on Medicaid and health spending in the next decade.
Managed Care Cast
July 1st 2025

Why Collaborative Care Is the Path Forward for Mental Health Care: Anna Bobb, MPH

Giuliana Grossi Anna Bobb, MPH
Explore how the Collaborative Care Model enhances mental health access in this episode featuring Anna Bobb, MPH, executive director of the Path Forward coalition.
A cornerstone of the proposed guidance is the emphasis on robust clinical trial design and appropriate patient selection. | Image Credit: wladimir1804 - stock.adobe.com
July 10th 2025

FDA Releases Draft Guidance for MDS Drug Development

Sabrina Serani
The FDA's new guidance shapes drug development for myelodysplastic syndromes (MDS), emphasizing trial design, patient selection, and safety reporting for better treatment outcomes.
Image credit: Canva Illustration | Mary Caffrey
July 9th 2025

Using AI for the Medical Note: Game Changer or a Bridge Too Far?

Mary Caffrey
During the “Tech Innovations in Community Oncology” meeting from Tennessee Oncology, oncologists explore artificial intelligence (AI) tools like DeepScribe to enhance documentation efficiency, reduce burnout, and improve patient engagement in clinical settings.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo